Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | LGMN | Q99538 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443433 | 0.93 | KEAP1 (0.64) | KEAP1ADRA2CLGMNGAAMEN1 | |
| SCHEMBL127620 | 0.93 | KEAP1 (0.64) | KEAP1ADRA2CLGMNGAAMEN1 | |
| Hydrochloric Acid SCHEMBL23536416 | 0.91 | KEAP1 (0.62) | KEAP1ADRA2CLGMNGAAMEN1 | |
| Hydrochloric Acid SCHEMBL9424019 | 0.91 | KEAP1 (0.62) | KEAP1ADRA2CLGMNGAAMEN1 | |
| SCHEMBL23122504 | 0.86 | KEAP1 (0.49) | KEAP1ADRA2CLGMNGAAMEN1 | |
| Aniline SCHEMBL22169106 | 0.86 | LGMN (0.57) | KEAP1ADRA2CLGMNGAAMEN1 | |
| SCHEMBL484010 | 0.82 | KEAP1 (0.95) | KEAP1ADRA2CGAAMEN1KMT2A | |
| SCHEMBL29938274 | 0.82 | KEAP1 (0.95) | KEAP1ADRA2CGAAMEN1KMT2A | |
| SCHEMBL30664040 | 0.82 | KEAP1 (0.87) | KEAP1ADRA2CGAAMEN1KMT2A | |
| SCHEMBL73609 | 0.81 | KEAP1 (1.00) | KEAP1ADRA2CGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | KEAP1 1775/4885ADRA2C 750/4885LGMN 3684/4885 |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | KEAP1 1485/4885ADRA2C 161/4885LGMN 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.